These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 10803040)

  • 1. [Pharma-clinics. Medication of the month. Telmisartan (Micardis)].
    Kulbertus H
    Rev Med Liege; 2000 Jan; 55(1):57-60. PubMed ID: 10803040
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Telmisartan.
    McClellan KJ; Markham A
    Drugs; 1998 Dec; 56(6):1039-44; discussion 1045-6. PubMed ID: 9878991
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Telmisartan: a review of its use in hypertension.
    Sharpe M; Jarvis B; Goa KL
    Drugs; 2001; 61(10):1501-29. PubMed ID: 11558835
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Telmisartan/hydrochlorothiazide: in the treatment of essential hypertension.
    Fenton C; Keating GM; Scott LJ
    Drugs; 2003; 63(19):2013-26; discussion 2027-8. PubMed ID: 12962518
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Telmisartan: a review of its pharmacodynamic and pharmacokinetic properties.
    Deppe S; Böger RH; Weiss J; Benndorf RA
    Expert Opin Drug Metab Toxicol; 2010 Jul; 6(7):863-71. PubMed ID: 20509777
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dose response and safety of telmisartan in patients with mild to moderate hypertension.
    Smith DH; Matzek KM; Kempthorne-Rawson J
    J Clin Pharmacol; 2000 Dec; 40(12 Pt 1):1380-90. PubMed ID: 11185637
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Angiotensin II receptor blocker telmisartan: effect on 24-hour blood pressure profile and left ventricular hypertrophy in patients with hypertension].
    Ivanova OV; Fomicheva OA; Sergakova LM; Chernova NA; Rogoza AN; Karpov YA
    Kardiologiia; 2002; 42(2):45-9. PubMed ID: 12494207
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Pharmacological and clinical profile of telmisartan, a selective angiotensin II type-1 receptor blocker].
    Chachin M; Ohmura T; Hayashi N; Nishimura Y; Satoh H
    Nihon Yakurigaku Zasshi; 2004 Jul; 124(1):31-9. PubMed ID: 15226620
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ambulatory blood pressure monitoring to assess the comparative efficacy and duration of action of a novel new angiotensin II receptor blocker--telmisartan.
    Neutel JM
    Blood Press Suppl; 2001; 1():27-32. PubMed ID: 11333011
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical pharmacology of telmisartan:
    Keefe DL
    J Clin Pharmacol; 2000 Dec; 40(12 Pt 1):1311. PubMed ID: 11185628
    [No Abstract]   [Full Text] [Related]  

  • 11. Inhibitory effect of telmisartan on the blood pressure response to angiotensin II challenge.
    Stangier J; Su CA; van Heiningen PN; Meinicke T; van Lier JJ; de Bruin H; Tamminga WJ; Jonkman JH
    J Cardiovasc Pharmacol; 2001 Nov; 38(5):672-85. PubMed ID: 11602814
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Telmisartan (micardis) -- an antagonist of angiotensin 2 of type 1 receptors: another antihypertensive drug or something greater?].
    Chazova IE
    Ter Arkh; 2003; 75(6):89-91. PubMed ID: 12920969
    [No Abstract]   [Full Text] [Related]  

  • 13. Pharmacokinetics of orally and intravenously administered telmisartan in healthy young and elderly volunteers and in hypertensive patients.
    Stangier J; Su CA; Roth W
    J Int Med Res; 2000; 28(4):149-67. PubMed ID: 11014323
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro and in vivo characterization of the activity of telmisartan: an insurmountable angiotensin II receptor antagonist.
    Maillard MP; Perregaux C; Centeno C; Stangier J; Wienen W; Brunner HR; Burnier M
    J Pharmacol Exp Ther; 2002 Sep; 302(3):1089-95. PubMed ID: 12183667
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Telmisartan: a different angiotensin II receptor blocker protecting a different population?
    Burnier M
    J Int Med Res; 2009; 37(6):1662-79. PubMed ID: 20146864
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety, efficacy, and pharmacokinetics of telmisartan in pediatric patients with hypertension.
    Wells TG; Portman R; Norman P; Haertter S; Davidai G; Fei Wang
    Clin Pediatr (Phila); 2010 Oct; 49(10):938-46. PubMed ID: 20724342
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Pharma-clinics. The drug of the month. Candesartan (Atacand)].
    Kulbertus H
    Rev Med Liege; 1999 Jun; 54(6):557-60. PubMed ID: 10446528
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Telmisartan: a review of its use in the management of hypertension.
    Battershill AJ; Scott LJ
    Drugs; 2006; 66(1):51-83. PubMed ID: 16398568
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics of repeated oral doses of amlodipine and amlodipine plus telmisartan in healthy volunteers.
    Stangier J; Su CA
    J Clin Pharmacol; 2000 Dec; 40(12 Pt 1):1347-54. PubMed ID: 11185633
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Telmisartan inhibits beta2-integrin MAC-1 expression in human T-lymphocytes.
    Link A; Lenz M; Legner D; Böhm M; Nickenig G
    J Hypertens; 2006 Sep; 24(9):1891-8. PubMed ID: 16915040
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.